Top

BMC Cancer

Published in:

Open Access 01-12-2021 | Research

Trends in survival from myeloma, 1990–2015: a competing risks analysis

Authors: Mary Jane Sneyd, Andrew R. Gray, Ian M. Morison

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Myeloma survival has greatly increased over past decades. We investigated trends in survival over time in New Zealand by age, ethnicity, and geography and thus examined potential inequalities among these population subgroups.

Methods

From data supplied by the New Zealand Ministry of Health, all new diagnoses of multiple myeloma (ICD-10 code C90) between 1990 and 2016 were extracted, as well as their matched mortality data. Cox’s proportional hazards regression and competing risks regression were used to estimate multivariable survival functions.

Results

Between 1 January 1990 and 1 December 2015, 6642 myeloma cases were registered by the New Zealand Cancer Registry. Although survival from myeloma increased substantially from 1990–1994 to 2010–2015, 5-year survival was still only about 60% in 2010–2015. The greatest improvement in survival was for people aged 60–69 years at diagnosis. Using Cox’s proportional hazards regression, Māori showed an increased risk of myeloma death but this was predominantly due to differences in competing risks among ethnic groups. Competing risks analysis found the greatest improvement in myeloma survival in Pacific Islanders, and in 2010–2015 Māori had better survival than other ethnicities. Myeloma survival improved significantly over time in all regional health authorities but in all time periods the Central and Southern regions had significantly poorer survival than the Midland region.

Conclusions

Improvements in myeloma survival have been unequal across subgroups and regions in New Zealand. Detailed information about utilization of chemotherapeutic agents and transplantation in New Zealand is not available. This information, as well as more detailed hematological data, is essential to further explore the relationships and reasons for differing myeloma survival in population subgroups of New Zealand.

Available only for authorised users

Samy E, Ross J, Bolton E, Morris E, Oliver S. Variation in incidence and survival by ethnicity for patients with myeloma in England (2002-2008). Leuk Lymphoma. 2015;56(9):2660–7. https://doi.org/10.3109/10428194.2014.1003060.CrossRefPubMed

GLOBOCAN 2012 v1.0. Cancer incidence and mortality worldwide: IARC; 2013. [cited 29/10/14]. Available from: http://globocan.iarc.fr

Sneyd M, Cox B, Morison I. Trends in myeloma incidence, mortality and survival in New Zealand (1985-2016). Cancer Epidemiol. 2019;60:55–9. https://doi.org/10.1016/j.canep.2019.03.006.CrossRefPubMed

Renshaw C, Ketley N, Moller H, Davies E. Trends in the incidence and survival of multiple myeloma in south East England 1985-2004. BMC Cancer. 2010;10(1):74–81. https://doi.org/10.1186/1471-2407-10-74.CrossRefPubMedPubMedCentral

Rachet B, Mitry E, Shah A, Cooper N, Coleman M. Survival from multiple myeloma in England and Wales up to 2001. Br J Cancer. 2008;99(S1):110–2.CrossRef

Pulte D, Redaniel M, Brenner H, Jansen L, Jeffreys M. Recent improvement in survival of patients with multiple myeloma: variation by ethnicity. Leuk Lymphoma. 2014;55(5):1083–9. https://doi.org/10.3109/10428194.2013.827188.CrossRefPubMed

Greenberg A, Vachon C, Rajkumar S. Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites. Leukemia. 2012;26(4):609–14. https://doi.org/10.1038/leu.2011.368.CrossRefPubMed

Verma P, Howard R, Weiss B. The impact of race on outcomes of autologous transplantation in patients with multiple myeloma. Am J Hematol. 2008;83(5):355–8. https://doi.org/10.1002/ajh.21139.CrossRefPubMed

Hari P, Majhail N, Zhang M-J, Hassebroek A, Siddiqui F, Ballen A, et al. Race and outcomes of autologous hematopoietic cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2010;16(3):395–402. https://doi.org/10.1016/j.bbmt.2009.11.007.CrossRefPubMed

10.

Attal M, Harousseau J-L, Stoppa A-M, Sotto J-J, Fuzibet J-G, Rossi J-F, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335(2):91–7. https://doi.org/10.1056/NEJM199607113350204.CrossRefPubMed

11.

Martino M, Recchia A, Fedele R, Neri S, Vincelli I, Moscato T, et al. The role of tandem stem cell transplantation for multiple myeloma patients. Expert Opin Biol Ther. 2016;16(4):515–34. https://doi.org/10.1517/14712598.2016.1136285.CrossRefPubMed

12.

Ministry of Health. Mortality data and stats. Wellington, New Zealand; 2014. updated June, 2014.

13.

Blimark C, Turesson I, Genell A, Ahlberg L, Björkstrand B, Carlson K, et al. Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish myeloma registry. Haematologica. 2018;103(3):506–13. https://doi.org/10.3324/haematol.2017.178103.CrossRefPubMedPubMedCentral

14.

van Montfort K, Fennema P, Ghidey W. Competing risks and survival analysis. In: Van Montfort KOJ, Ghidey W, editors. Developments in Statistical Evaluation of Clinical Trials. Berlin: Springer-Verlag; 2014. p. 85–96.

15.

Kim H. Cumulative incidence in competing risks data and competing risks regression analysis. Clin Cancer Res. 2007;13(2):559–65. https://doi.org/10.1158/1078-0432.CCR-06-1210.CrossRefPubMed

16.

Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509. https://doi.org/10.1080/01621459.1999.10474144.CrossRef

17.

Statistics New Zealand. Ethnic groups in New Zealand. Wellington, New Zealand: Statistics New Zealans; 2014.

18.

Ríos-Tamayo R, Sánchez M, Puerta J, Sáinz J, Chang D, Rodríguez T, et al. Trends in survival of multiple myeloma: a thirty-year population-based study in a single institution. Cancer Epidemiol. 2015;39(5):693–9. https://doi.org/10.1016/j.canep.2015.08.002.CrossRefPubMed

19.

Andres M, Feller A, Arndt V. The NICER working group. Trends of incidence, mortality, and survival of multiple myeloma in Switzerland between 1994 and 2013. Cancer Epidemiol. 2018;53:105–10. https://doi.org/10.1016/j.canep.2018.01.015.CrossRefPubMed

20.

Pulte D, Gondos A, Brenner H. Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data. Oncologist. 2011;16(11):1600–3. https://doi.org/10.1634/theoncologist.2011-0229.CrossRefPubMedPubMedCentral

21.

Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood. 2008;111(5):2521–6. https://doi.org/10.1182/blood-2007-08-104984.CrossRefPubMed

22.

Ludwig H, Durie B, Bolejack V, Turesson I, Kyle R, Blade J, et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10549 patients from the international myeloma working group. Blood. 2008;111(8):4039–47. https://doi.org/10.1182/blood-2007-03-081018.CrossRefPubMedPubMedCentral

23.

Kumar S, Dispenzieri A, Lacy M, Gertz M, Buadi F, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122–8. https://doi.org/10.1038/leu.2013.313.CrossRefPubMed

24.

Schaapveld M, Visser O, Siesling S, Schaar C, Zweegman S, Vellenga E. Improved survival among younger but not among older patients with multiple myeloma in the Netherlands, a population-based study since 1989. Eur J Cancer. 2010;46(1):160–9. https://doi.org/10.1016/j.ejca.2009.07.006.CrossRefPubMed

25.

Pulte D, Nie L, Gormley N, Goldberg K, McKee A, Farrell A, et al. Survival of ethnic and racial minority patients with multiple myeloma treated with newer medications. Blood Adv. 2018;2(2):116–9. https://doi.org/10.1182/bloodadvances.2017010512.CrossRefPubMedPubMedCentral

Title: Trends in survival from myeloma, 1990–2015: a competing risks analysis
Authors: Mary Jane Sneyd
Andrew R. Gray
Ian M. Morison
Publication date: 01-12-2021
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08544-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

NOX4-derived ROS-induced overexpression of FOXM1 regulates aerobic glycolysis in glioblastoma

Comparative analysis of patients with upper urinary tract urothelial carcinoma in black-foot disease endemic and non-endemic area

Community oncologists’ perceptions and utilization of large-panel genomic tumor testing

Preferences of first-degree relatives of gastric cancer patients for gastric cancer screening: a discrete choice experiment

Effect of d-limonene and its derivatives on breast cancer in human trials: a scoping review and narrative synthesis

Complete remission of metastatic osteosarcoma using combined modality therapy: a retrospective analysis of unselected patients in China

Keynote webinar | Spotlight on antibody–drug conjugates in cancer